IL-21 in cancer immunotherapy: At the right place at the right time

Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth c...

Descripción completa

Detalles Bibliográficos
Autores principales: Santegoets, Saskia JAM, Turksma, Annelies W., Powell Jr., Daniel J, Hooijberg, Erik, de Gruijl, Tanja D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716748/
https://www.ncbi.nlm.nih.gov/pubmed/23894713
http://dx.doi.org/10.4161/onci.24522
_version_ 1782277590556344320
author Santegoets, Saskia JAM
Turksma, Annelies W.
Powell Jr., Daniel J
Hooijberg, Erik
de Gruijl, Tanja D
author_facet Santegoets, Saskia JAM
Turksma, Annelies W.
Powell Jr., Daniel J
Hooijberg, Erik
de Gruijl, Tanja D
author_sort Santegoets, Saskia JAM
collection PubMed
description Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth characteristics and a minimal risk of detrimental side effects.
format Online
Article
Text
id pubmed-3716748
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37167482013-07-26 IL-21 in cancer immunotherapy: At the right place at the right time Santegoets, Saskia JAM Turksma, Annelies W. Powell Jr., Daniel J Hooijberg, Erik de Gruijl, Tanja D Oncoimmunology Author's View Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth characteristics and a minimal risk of detrimental side effects. Landes Bioscience 2013-06-01 2013-04-16 /pmc/articles/PMC3716748/ /pubmed/23894713 http://dx.doi.org/10.4161/onci.24522 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Santegoets, Saskia JAM
Turksma, Annelies W.
Powell Jr., Daniel J
Hooijberg, Erik
de Gruijl, Tanja D
IL-21 in cancer immunotherapy: At the right place at the right time
title IL-21 in cancer immunotherapy: At the right place at the right time
title_full IL-21 in cancer immunotherapy: At the right place at the right time
title_fullStr IL-21 in cancer immunotherapy: At the right place at the right time
title_full_unstemmed IL-21 in cancer immunotherapy: At the right place at the right time
title_short IL-21 in cancer immunotherapy: At the right place at the right time
title_sort il-21 in cancer immunotherapy: at the right place at the right time
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716748/
https://www.ncbi.nlm.nih.gov/pubmed/23894713
http://dx.doi.org/10.4161/onci.24522
work_keys_str_mv AT santegoetssaskiajam il21incancerimmunotherapyattherightplaceattherighttime
AT turksmaanneliesw il21incancerimmunotherapyattherightplaceattherighttime
AT powelljrdanielj il21incancerimmunotherapyattherightplaceattherighttime
AT hooijbergerik il21incancerimmunotherapyattherightplaceattherighttime
AT degruijltanjad il21incancerimmunotherapyattherightplaceattherighttime

Ejemplares similares